Gilead Surges On HIV In Q3, But Investors Pull Back With Myogen Purchase

The strength of Gilead's HIV portfolio, and particularly its newest addition Atripla, drew investor confidence in the third quarter, with the biopharmaceutical firm gaining 16.2% to reach a quarterly high close of 68.77 Sept. 29